Triclosan Lacks Solo Use Data Needed To Join Gingivitis Monograph – Colgate
This article was originally published in The Tan Sheet
Executive Summary
Triclosan should not be included in the antigingivitis OTC drug products monograph because sufficient data is not available on its use as a sole active ingredient, Colgate maintains
You may also be interested in...
Triclosan Antigingivitis Effectiveness Data Questioned by P&G, Colgate
Procter & Gamble and Colgate object to the inclusion of triclosan as a Category I ingredient in the antigingivitis monograph as proposed by triclosan producer Ciba
FDA on triclosan
Agency solicits safety and efficacy data on .3% triclosan as an antigingivitis ingredient in dental pastes and oral rinses in a notice published in the July 6 Federal Register. FDA will review the data to determine if the ingredient can be generally recognized as safe and effective under the OTC oral health care drug products monograph. Comments will be accepted up to 90 days following publication of the notice. The review responds to a time and extent application filed by Ciba Specialty Chemicals last November (1"The Tan Sheet" Dec. 8, 2003, p. 8). Ciba stated that 3.5 bil. units of dental paste containing triclosan have been used in 13 selected countries over the past six years. Triclosan currently is marketed in the U.S. as an oral care ingredient through an NDA filed by Colgate-Palmolive...
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application